Twenty-six patients with breast cancer who had relapsed after previously receiving high-dose chemotherapy and autologous hematopoietic cell support received a second course of high-dose cytoreductive therapy and autologous hematopoietic cell support as salvage therapy. Several different high-dose therapy regimens were employed for the second transplant, including a radiolabeled immunoconjugate. Two patients died of treatment-related complications. The remaining 24 patients relapsed a median of 126 (range 22-635) days after salvage transplant. All have since died. The median survival after salvage transplant was 362 (range 31-931) days. We conclude that second courses of high-dose therapy as salvage treatment are generally well-tolerated but their efficacy is modest. Alternative treatment strategies are needed for these patients. Keywords: breast cancer; second autologous transplants; salvage therapy Breast cancer is the most frequent indication for high-dose chemotherapy (HDCT) and autologous hematopoietic cell support (AHCS) in the United States.
Breast cancer is the most frequent indication for high-dose chemotherapy (HDCT) and autologous hematopoietic cell support (AHCS) in the United States. 1 While initial results, especially for patients with high-risk primary breast cancer, have been especially encouraging, 1,2 only 15-20% of patients with metastatic breast cancer are alive and diseasefree 3 years after HDCT. 1, [3] [4] [5] Most patients who are transplanted for metastatic disease relapse and the appropriate treatment for these patients is unclear.
Patients who relapse after HDCT may be candidates for phase I studies, which may include high-dose therapy trials. There are substantial data supporting the efficacy of second marrow transplants in selected patients with hematologic malignancies who relapse after their first transplant. [6] [7] [8] [9] It is unclear whether this strategy is safe and effective for patients with breast cancer. In an effort to address these questions, we reviewed the records of all patients who received high-dose cytoreductive therapy as salvage treatment for breast cancer who had relapsed or progressed after previous high-dose chemotherapy at the University of Colorado and at Duke University.
Methods

Patient selection
All patients with breast cancer who had relapsed after HDCT and who received a second course of high-dose cytoreductive therapy with autologous hematopoietic support at the University of Colorado or at Duke University Medical Center were included in this analysis. Sites of disease at the time of second HDT are shown in Table 1 . All patients were required to have satisfactory end-organ function as demonstrated by pulmonary function tests (forced expiratory volume and diffusing capacity у60% of predicted), radionuclide ventriculography (ejection fraction у45% at rest, with exercise augmentation), 24-h urine collection for creatinine clearance (у60 ml/min), AST and total bilirubin р1.5 × the upper limit of normal for the patient's referring institution, and be seronegative for the human immunodeficiency virus.
Treatment
Patients were enrolled in phase I trials at our institutions and received second courses of high-dose therapy between January 1988 and August 1995 ( (12) 1 (4) product support, use of colony-stimulating factors, antibiotics and other supportive care were administered according to institutional guidelines.
Progenitor cell support
Marrow and/or peripheral blood progenitor cells were collected and administered as per concurrent institutional studies (Table 1) . Some patients received cells that were positively selected for CD34. 14 One patient received cells that were purged with a combination of monoclonal antibodies and 4-hydroperoxycyclophosphamide. 15 Progenitor cells were suspended in 72.5% tissue culture medium 199 (TC-199), 7.5% dimethyl sulfoxide and 20% autologous plasma and cryopreserved using a controlled-rate freezing method, 14 and stored at −196°C.
Statistics
Overall and progression-free survival were estimated using the method of Kaplan and Meier. 16 Survivals were compared between groups using the logrank test. One patient underwent a second transplant because of persistently elevated tumor markers without evidence of disease progression following the first transplant. Her survival and overall survival are analyzable with respect to stage at first transplant. She is not analyzable with respect to progression-free interval after first transplant or interval from relapse/progression following first transplant to second transplant.
Results
Patient characteristics
Twenty-six patients were treated with high-dose therapy for relapsed or progressive disease after previous treatment with high-dose chemotherapy. Twenty-one patients were initially diagnosed with primary breast cancer while five patients presented with distant metastases at initial diagnosis. Twenty patients received their first transplant for metastatic breast cancer while six underwent initial HDCT for high-risk primary breast cancer. The median progression-free interval after the first course of HDCT was 341 (range 176-970) days. The median time from relapse or progression after first transplant to second transplant was 135 (range 18-829) days. Seventeen patients were treated with additional conventional-dose chemotherapy prior to their second transplant. Of these, six achieved partial responses, eight did not respond and two progressed and one was not evaluable.
Engraftment
Nineteen patients were evaluable for engraftment. The four patients treated with radiolabeled monoclonal antibody were cared for by their referring physicians after discharge from the hospital and did not routinely have complete daily blood counts. Two patients died of toxicity, one before engrafting either white cells or platelets and the second after myeloid engraftment but prior to platelet engraftment. A third patient died of recurrent disease before platelet engraftment.
The number of days to reach absolute neutrophil count of 500/l and platelet count of 20 000/l were 13 (range 7-24) and 21 (range 9-45), respectively.
Hospitalization, survival and progression-free survival after second HDT
Two patients (8%) died of multiorgan failure within 30 days of their second HDT treatment. Four patients were treated with radiolabeled monoclonal antibody and were hospitalized only until their total body radioactivity was less than 30 mCi. The median duration of hospitalization for the remaining 20 patients was 20 (range 0-30) days.
Twenty-four patients were evaluable for response to HDT after failure of previous HDCT. There were two complete responses (8%) and five partial responses (21%). Nine patients with measurable disease were non-responders (37%). Eight patients (33%) did not have evaluable disease and could not be assessed for response. The median time to disease progression or relapse after second HDT was 126 (range 22-635) days (Figure 1 ). All patients have died. The median survival after second transplant was 362 (range 31-931) days (Figure 1) .
We evaluated stage at first transplant, progression-free interval from first transplant to subsequent relapse, and time from relapse after first transplant to second HDT as possible prognostic markers for outcome after second HDT. There were no statistically significant differences among patients who were first transplanted for high-risk primary breast cancer vs metastatic disease, for those with progression-free intervals from first HDCT to subsequent relapse of 12 or more months vs less than 12 months, or for interval from relapse after first transplant to second HDT of 6 or fewer months vs more than 6 months ( Table 2) .
We also evaluated whether response to standard-dose chemotherapy immediately prior to the second transplant influenced outcome (Table 3) . Seventeen patients were treated with chemotherapy prior to second transplant while eight were not. Among evaluable patients, there was no statistical difference in survival or progression-free survival between patients who did not receive conventional-dose chemotherapy prior to second transplant and patients who did receive conventional-dose chemotherapy, irrespective of whether they responded or not (Table 3) .
Discussion
Breast cancer is the leading indication for stem cell-supported therapy in the United States. The Autologous Blood and Marrow Transplant Registry of North America reported that more than 5800 patients with breast cancer received HDCT with autologous hematopoietic cell support, the majority of whom had metastatic disease.
1 Long-term progression-free survival for patients with metastatic breast cancer after HDCT has been disappointing. [3] [4] [5] There is little information regarding survival after relapse from transplant for breast cancer. Singh et al 17 examined survival duration after relapse subsequent to high-dose chemotherapy for advanced or high-risk breast cancer. Median survival was 8 months. Survival was better in patients who had chemotherapy-responsive disease before transplant than in those who had resistant disease. Whether patients were chemotherapy-sensitive after relapse following transplant and whether this influenced survival was not reported. Martin et al 18 used a combination of intramuscular methotrexate, oral tegafur and uracil and oral leucovorin to treat 24 patients with metastatic breast cancer who had relapsed after HDCT. 18 The response rate was 38% and included one patient who achieved a complete response. Median progression-free and overall survival were 6 and 9 months, respectively.
We examined our experience using high-dose therapy with progenitor cell support as salvage treatment for patients who had relapsed or progressed after previous treatment with high-dose chemotherapy. Although several patients did well after a second course of high-dose therapy, the median progression-free and overall survivals were approximately 4 and 12 months, respectively. Of the 13 patients who survived more than 1 year from second highdose therapy, most were being treated for recurrent disease.
There are considerable data from the North American Blood and Marrow Transplant Registry showing that patients with refractory disease do very poorly after a first transplant. Is there any reason we should expect them to do better with a second transplant? It is important to note that these patients did not receive 'tandem' transplants. This paper does not address whether a tandem approach is superior to a single high-dose therapy program.
How then should patients who relapse after high-dose chemotherapy be treated? A second high-dose therapy program with autologous cell support is, in our opinion, ineffective. However, the evaluation of other therapeutic approaches is reasonable and appropriate for these patients. For example, allogeneic transplantation for breast cancer requires further study. Several centers have reported possible graft-versus-breast cancer effects, such as the resolution of metastases which develop after allotransplantation by the withdrawal of GVHD treatment (and the coincident exacerbation of GVHD). 19 Patients who have failed a previous autologous transplant and have good organ function would be appropriate candidates for such studies. The discovery of donor cells infiltrating malignant lesions would provide additional evidence for a graft-versus-breast cancer effect. 20 Other therapeutic modalities, such as monoclonal antibody therapy, gene transfer therapy, and biological approaches need further study and patients who have failed a previous transplant would be appropriate candidates for these approaches, as well. These approaches are actively being investigated in our programs.
